Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update - Candlesense
ZLNA Earnings

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.

Related Questions

How will the Q2 2025 earnings and cash position affect Zelluna's short-term valuation? What updates were provided on the TCR‑NK therapy pipeline and regulatory timelines? How does Zelluna's performance and outlook compare to other off‑the‑shelf cell‑therapy peers?
Find similar articles on Candlesense globenewswire